/ 2 items

#BSX↓

BSX/ 02/04/2026 · 9:00 AM

Boston Scientific Shares Drop Despite Strong Q4 as 2026 Outlook Disappoints

Boston Scientific (BSX) reports strong Q4 2025 earnings but shares fall over 10% on modest 2026 guidance. Revenue growth expected to slow to 10-11% from 15.8% in 2026.

Featured/ PEN/ 01/15/2026 · 7:14 AM

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal

Boston Scientific announces acquisition of Penumbra for $14.5B, expanding into blood clot removal and neurovascular treatments to address cardiovascular diseases.